Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2020 1
2022 2
2024 1
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Facial synthesis of key intermediate of obeticholic acid via Pd-catalyzed Kumada-Tamao-Corriu cross-coupling reaction.
Di X, Han J, Zou S, Wei X, Huang Q, Zhu J, Wang Y, Zhong L, Wang Q. Di X, et al. Steroids. 2020 Aug;160:108657. doi: 10.1016/j.steroids.2020.108657. Epub 2020 May 18. Steroids. 2020. PMID: 32439409
Obeticholic acid (OCA) is used to treatment for Primary Biliary Cholangitis and other Famesoid X Receptor related diseases. ...
Obeticholic acid (OCA) is used to treatment for Primary Biliary Cholangitis and other Famesoid X Receptor related diseases. .. …
Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP, Steinman L. Ho PP, et al. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1600-5. doi: 10.1073/pnas.1524890113. Epub 2016 Jan 25. Proc Natl Acad Sci U S A. 2016. PMID: 26811456 Free PMC article.
Bile acids are ligands for the nuclear hormone receptor, farnesoid X receptor (FXR). The bile acid-FXR interaction regulates bile acid synthesis, transport, and cholesterol metabolism. ...In this study, we found that FXR knockout mice had more disease severity in ex …
Bile acids are ligands for the nuclear hormone receptor, farnesoid X receptor (FXR). The bile acid-FXR interaction regulates bile …
Primary biliary cholangitis (PBC): evolving approaches and expert perspectives.
Invernizzi P, Aghemo A, Calvaruso V, Lleo A, Marzioni M, Piscaglia F, Rigamonti C, Vespasiani Gentilucci U, Brillanti S, Carbone M, Cazzagon N, Lampertico P. Invernizzi P, et al. Expert Rev Gastroenterol Hepatol. 2026 Jan;20(1):17-28. doi: 10.1080/17474124.2025.2601220. Epub 2025 Dec 19. Expert Rev Gastroenterol Hepatol. 2026. PMID: 41399111 Free article. Review.
If untreated, PBC can progress to cirrhosis, liver failure and need for transplantation, significantly impacting life expectancy. AREAS COVERED: Ursodeoxycholic acid (UDCA) remains the only approved first-line therapy. The recent withdrawal of obeticholic acid …
If untreated, PBC can progress to cirrhosis, liver failure and need for transplantation, significantly impacting life expectancy. AREAS COVE …
Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice.
Wang H, Zhang J, Zhang X, Zhao N, Zhou Z, Tao L, Fu L, Peng S, Chai J. Wang H, et al. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166556. doi: 10.1016/j.bbadis.2022.166556. Epub 2022 Sep 23. Biochim Biophys Acta Mol Basis Dis. 2022. PMID: 36154893 Free article.
Cholestasis is characterized by intrahepatic accumulation of bile acids (BAs), resulting in liver injury, fibrosis, and liver failure. To date, only ursodeoxycholic acid and obeticholic acid have been approved for the treatment of cholestasis. As fluorofenido …
Cholestasis is characterized by intrahepatic accumulation of bile acids (BAs), resulting in liver injury, fibrosis, and liver failure. To da …
NR1H4 ameliorates Parkinson's disease via inhibiting astrocyte activation and neuroinflammation in a CEBPβ/NF-κB dependent manner.
Li J, Liu H, Hu X, Zhang S, Yu Q, Kuang G, Liu L, Yu D, Huang J, Xia Y, Wang T, Xiong N. Li J, et al. Int Immunopharmacol. 2024 Dec 5;142(Pt A):113087. doi: 10.1016/j.intimp.2024.113087. Epub 2024 Sep 5. Int Immunopharmacol. 2024. PMID: 39241522 Free article.
Previous studies suggested the protective role of NR1H4 in various diseases related to inflammation, whether NR1H4 participates in PD progression remains unknown. To investigate the role of NR1H4 in neuroinflammation regulation, especially astrocyte activation during PD …
Previous studies suggested the protective role of NR1H4 in various diseases related to inflammation, whether NR1H4 participates in PD …
Mechanism of FXR signaling: from liver inflammation to hepatocellular carcinoma.
Qiuluo C, Guiqun H, Xue H, Ying Z. Qiuluo C, et al. Biochem Biophys Rep. 2026 Aug 26;47:102753. doi: 10.1016/j.bbrep.2026.102753. eCollection 2026 Sep. Biochem Biophys Rep. 2026. PMID: 42699277 Free PMC article. Review.
METHODS: A systematic review was performed to integrate FXR's key regulatory mechanisms in bile acid homeostasis, inflammatory signaling, metabolic reprogramming, tumor pathways, and the tumor immune microenvironment. ...FXR activation inhibits STAT3 phosphorylation, glyco …
METHODS: A systematic review was performed to integrate FXR's key regulatory mechanisms in bile acid homeostasis, inflammatory signal …
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C, Wedemeyer H, Mason A, Hirschfield GM, Levy C, Kowdley KV, Milkiewicz P, Janczewska E, Malova ES, Sanni J, Koo P, Chen J, Choudhury S, Klickstein LB, Badman MK, Jones D. Schramm C, et al. JHEP Rep. 2022 Jul 21;4(11):100544. doi: 10.1016/j.jhepr.2022.100544. eCollection 2022 Nov. JHEP Rep. 2022. PMID: 36267872 Free PMC article.
BACKGROUND & AIMS: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary biliary cholangitis (P …
BACKGROUND & AIMS: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evalu …